

10<sup>th</sup> February 2023

The Manager  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

Sir,

**Sub: Newspaper Advertisement - Postal Ballot Notice**

Please find enclosed copies of the newspaper advertisement titled 'Notice of Postal Ballot and E-voting Information'. The advertisements appeared in Financial Express and Mumbai Lakshadweep (Marathi version) in today's edition (10<sup>th</sup> February 2023).

Kindly take on record of the above.

Thanking you,  
Yours faithfully,  
**For Sunshield Chemicals Limited**

**Amit Kumashi**  
**Company Secretary**





Regd. Office : 214, Empire House, Dr. D. N. Road, Ent. A. K. Nayak Marg, Fort, Mumbai - 400001  
Tel Nos : 22071501-06 Fax : 22071514 Email : investors@karmaenergy.com  
Visit us at : www.karmaenergy.co

### Extract of the Financial Results for the Quarter & Nine Months Ended 31.12.22

(Rs. in Lac except EPS data)

Particulars	Quarter Ended		Nine Months Ended	
	31-12-22	31-12-21	31-12-22	31-12-21
	Unaudited	Unaudited	Unaudited	Unaudited
1 Total Income from Operations	202.50	797.51	1,232.40	2,603.88
2 Net Profit / (Loss) for the period before Tax	(161.22)	129.59	52.32	(17.85)
3 Net Profit / (Loss) for the period after Tax	(140.78)	136.70	162.61	43.04
4 Total Comprehensive Income for the period [Comprising Profits / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	(142.75)	119.81	149.45	34.37
5 Equity Share Capital	1,156.99	1,156.99	1,156.99	1,156.99
6 Earnings per Share of Rs. 10/- each [(for Continuing and Dis-continued Operations (not annualised)) Basic & Diluted	(1.22)	1.18	1.41	0.37

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results for Quarter and Nine Months Ended 31.12.22 is available on the websites of Stock Exchanges at and also on the Company's website at
- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 09.02.23
- The Company is primarily operating in the business of Generation of Power from Renewable Sources. Hence, there is only one business segment as per Ind-AS 108 - Operating Segments.
- As required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the review by the Statutory Auditors has been completed for the Quarter and Nine Months Ended 31.12.22 and the Report has been forwarded to the stock exchanges. The Report does not contain any qualification.
- Previous period's figures have been regrouped / reclassified wherever necessary.

## FINANCIAL EXPRESS



### Veranda Learning Solutions Limited

Registered Office Address: Old No 54, New No 34, Thirumalai Pillai Road, T.Nagar, Chennai-600017  
Corporate Identity Number : L74999TN2018PLC125880

Extract of the Unaudited Consolidated Financial Results for the Quarter and Nine Months ended December 31, 2022

S. No.	Particulars	(Rs.In.Lakhs)					
		Quarter Ended		Nine Months Ended		Year Ended	
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2021	December 31, 2021	March 31, 2022
1	Total Income from Operations	8,371.91	3,876.97	3,055.19	15,112.04	4,621.23	7,560.15
2	Net Profit/(Loss) for the period (before tax, Exceptional items and/or Extraordinary items)	(260.27)	(2,254.72)	(2,071.95)	(4,641.05)	(3,919.83)	(6,120.81)
3	Net Profit/(Loss) for the period before tax (after Exceptional items and/or Extraordinary items)	(260.27)	(2,254.72)	(2,071.95)	(4,641.05)	(3,919.83)	(6,120.81)
4	Net Profit/(Loss) for the period (after tax, Exceptional and/or Extraordinary Items (before discontinued operations)	65.92	(2,112.56)	(1,928.21)	(4,053.52)	(3,755.28)	(5,849.49)
5	Net Profit/(Loss) for the period after tax from continuing and discontinued operations (after Exceptional and/or Extraordinary items)	65.92	(2,112.56)	(1,928.21)	(4,053.52)	(3,755.28)	(5,849.49)
6	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	67.54	(2,117.10)	(1,925.82)	(4,066.09)	(3,755.17)	(5,855.46)
7	Equity Share Capital (Face Value of the share - Rs. 10/- each)	6,157.21	5,577.55	4,067.70	6,157.21	4,067.70	4,117.70
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year						3,580.28
9	Earnings Per Share (EPS) (after Extraordinary items) of Rs. 10/- each (Not annualised)						
	(A) For Continuing Operations						
	a) Basic	0.19	(3.79)	(5.95)	(7.04)	(10.31)	(16.96)
	b) Diluted	0.18	(3.79)	(5.95)	(7.04)	(10.31)	(16.96)

Notes :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 09th February 2023.
- The above extract is as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). Also, as required, the specified items of the unaudited Standalone financial results of the company are given below.

(Rs.in Lakhs)

S.No.	Particulars	STANDALONE				
		Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Year Ended
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	March 31, 2022
1	Turnover	3,942.06	481.88	415.61	4,850.22	1,352.43
2	Net Profit before Tax	1,609.78	(144.61)	(409.39)	1,231.86	(1,269.60)
3	Net Profit after Tax	1,601.68	(144.79)	(404.47)	1,225.21	(1,264.99)

- The above is an extract of the detailed format of quarterly unaudited financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The full format of these quarterly unaudited financial results is available on the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and on the website of the company (www.verandallearning.com).

Place : Chennai

Date: 9th February 2023

Kalpathi S Suresh  
Executive Director Cum Chairman  
DIN: 00526480

### VAISHALI PHARMA LTD.

CIN: L52310MH2008PLC181632

Corp. & Reg. Office: 706-709, 7<sup>th</sup> Floor, Aravali Business Centre, R. C. Patel Road, Off. Sodawala Lane, Borivali (West), Mumbai - 400092. | Tel.: +91-22-42171819 | E-mail: investor@vaishalipharma.com

### Extract of Un-Audited Financial Results for the Quarter ended December 31, 2022

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Half Year Ended	Half Year Ended	Year Ended
		30-DEC-22 (Unaudited)	30-SEP-22 (Unaudited)	30-DEC-21 (Unaudited)	30-DEC-22 (Unaudited)	30-DEC-21 (Unaudited)	31-Mar-22 (Audited)
1	Income from Operations	2,008.60	1,315.91	2,228.16	4,342.51	5,041.29	7,582.08
2	Net Profit before Tax, Exceptional items	354.94	265.90	214.31	822.32	509.43	572.83
3	Net Profit after tax, Exceptional items	266.20	199.42	160.72	616.74	382.08	402.36
4	Total Comprehensive Income	266.20	199.42	160.72	616.74	382.08	404.01
5	Equity Share Capital	1,054.62	1,054.62	1,054.62	1,054.62	1,054.62	1,054.62
6	Earnings Per Share						
	1. Basic:	2.52	1.89	1.52	5.85	3.62	3.82
	2. Diluted:	2.52	1.89	1.52	5.85	3.62	3.82

NOTE:-

- The above is an extract of the detailed format of the Un-Audited Financial Results for the Quarter ended December 31, 2022 filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015. The Detailed format of the Un-Audited Financial Results are available on the Stock Exchange Websites: - www.nseindia.com and on the Company Website: - www.vaishalipharma.com.
- The above results were reviewed by the Audit Committee, and approved by the Board of Directors at their respective meeting(s) held on February 06, 2022. Statutory auditors have carried out limited review of the above results.

By order of the Board  
For Vaishali Pharma Limited

Sd/-  
Atul Vasani  
Chairman & Managing Director

Date : February 09, 2022  
Place : Mumbai

### AURANGABAD MUNICIPAL CORPORATION, AURANGABAD

#### E-Tender Notice 2022-2023

#### Re-Tender Notice

E-Tender in B-1 form for the following work invited by City Engineer, Municipal Corporation, Aurangabad (Phone No. 0240-2333536-40) from Government Registered Contractors/Companies / Firms of Appropriate Category.

Sr. No.	Name of Work	Tender Amount Rs.
1	Construction of BT Road and retaining wall from Kille ark VIP Road (Naubat Gate) to Panchkva Bridge.	2,49,13,026.00

Details regarding the tender for the said works will be available on <http://mahatenders.gov.in> From. Dt. 09/02/2023. Administrator, Municipal Corporation, Aurangabad reserves all the rights to reject/cancel any or all tenders without assigning any reason.

Sd/-  
City Engineer  
Municipal Corporation Aurangabad

### SUNSHIELD CHEMICALS LTD

#### SUNSHIELD CHEMICALS LIMITED

Corporate Identity Number : L99999MH1986PLC041612

Regd. Office: 1501-A, Universal Majestic, P.L. Lokhande Marg, behind RBK International School, Chembur-West, Mumbai - 400 043

Phone No.: 25550126 E Mail : investorservices@sunshieldchemicals.com  
Website : www.sunshieldchemicals.com

#### NOTICE OF POSTAL BALLOT AND E-VOTING INFORMATION

Notice is hereby given that pursuant to the provisions of Section 108 and 110 of the Companies Act, 2013 ("the Act") read with Rule 20 and 22 of Companies (Management and Administration) Rules, 2014 ("the Rules") and other applicable provisions of the Act, the Rules and notifications made thereunder (including statutory modification or re-enactment thereof) as may be applicable, the General Circular 14/2020 dated April 8, 2020, 17/2020 dated 13th April, 2020, 22/2020 dated 15th June, 2020, 33/2020 dated 28th September, 2020, 39/2020 dated 31st December, 2020, 10/2021 dated 23rd June, 2021, 20/2021 dated 8th December, 2021, 3/2022 dated 5th May, 2022 and 11/2022 dated 28th December, 2022 issued by the Ministry of Corporate Affairs ("MCA Circulars"), the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and Secretarial Standard on General Meeting ("SS-2") issued by the Institute of Company Secretaries of India, the approval of the members of Sunshield chemicals Limited ("the Company") is being sought for the Resolutions listed below by means of Postal Ballot, only by way of remote e-voting process ("e-voting").

Sr.no.	Particulars	Resolution
1	Change in designation of Mr. Jeet Malhotra ( DIN : 07208234), Wholtime Director & Chief Executive Officer as Managing Director & Chief Executive Officer, effective, 3rd February 2023	Special

This Postal Ballot Notice dated 3<sup>rd</sup> February 2023 will also be available on the Company's website at [www.sunshieldchemicals.com](http://www.sunshieldchemicals.com) and website of BSE Limited at [www.bseindia.com](http://www.bseindia.com) as well as on website of National Securities Depository Limited ("NSDL") at [www.evoting.nsdl.com](http://www.evoting.nsdl.com)

In accordance with the aforesaid MCA circulars, the Company has sent the Postal Ballot Notice along with Explanatory Statement on 9<sup>th</sup> February, 2023, only through electronic means to those members whose names appear in the Register of Members of the Company or in the Register of Beneficial Owners maintained by the Depositories and whose email addresses are registered with the Company/Depositories as on Friday, 3<sup>rd</sup> February 2023 ("Cut-Off Date"). The voting rights of Members shall be in proportion to their shares in the paid-up equity share capital of the Company as on the Cut-Off date. Communication of assent or dissent of the Members whose names are recorded in the Register of Members of the Company or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-Off date will be entitled to cast their votes by remote e-voting. A person who is not a member as on the relevant date should treat this notice for information purpose only.

The Company has engaged the services of NSDL as the agency to provide remote e-voting facility to its members. Members may cast their votes during the period mentioned herein below:

• Commencement of e-voting – 9.00 a.m. (IST) on Tuesday, 14<sup>th</sup> February 2023

• End of e-voting – 5.00 p.m. (IST) on Wednesday, 15<sup>th</sup> March 2023

The e-voting module shall be disabled by NSDL thereafter. Once the vote on the resolution is cast by the Member, he/she shall not be allowed to change it subsequently.

The members whose e-mail address is not registered with the Company/Depositories, to receive the Postal ballot notice may send mail to [cs@nsdl.com](mailto:cs@nsdl.com) or on or before 5.00 p.m. IST, Wednesday, 8<sup>th</sup> March 2023.

For details relating to e-voting, please refer to the Postal Ballot notice. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on toll free no.: 1800 1020 990 and 1800 2244 30 or send a request at [evoting@nsdl.com](mailto:evoting@nsdl.com).

#### Scrutinizer for e-voting and declaration of e-voting results

The Board of Directors have appointed Mr. Prasen Nathani, of M/s. P. Nathani & Associates, Company Secretaries, Mumbai, as the Scrutinizer ("Scrutinizer") for conducting the Postal Ballot through remote e-voting process in a fair and transparent manner.

The resolution, if approved by requisite majority shall be deemed to have been passed on the last date of the e-voting i.e. Wednesday, 15<sup>th</sup> March 2023. The result of the Postal Ballot shall be on or before Friday, 17<sup>th</sup> March 2023. The said results together with the Scrutinizer's report will be communicated to BSE limited and shall also be displayed on the Company's website and NSDL's website. The Scrutinizer's decision on the validity of the Postal Ballot shall be Final.

For Sunshield Chemicals Limited  
Sd/-  
Amit Kumashi  
Company Secretary

Mumbai, 9<sup>th</sup> February 2023



### Orchid Pharma Limited

Regd. Office: 'Orchid Towers' #313, Valluvar Kottam High Road, Nungambakkam, Chennai - 600034, Tamil Nadu, India  
Ph. +91 - 44 - 2821 1000 / 2823 0000 Fax: +91 - 44 - 2821 1002 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com  
CIN : L24222TN1992PLC022994

#### STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rs.in Lakhs)

S. No.	Particulars	Standalone										Consolidated									
		Quarter ended	Quarter ended	Year to date	Corresponding	Year to date	Year	Quarter ended	Quarter ended	Year to date	Corresponding	Year to date	Year								
		December 31, 2022 (Unaudited)	September 30, 2022 (Unaudited)	figures December 31, 2022 (Unaudited)	quarter of previous year ended December 31, 2021 (Unaudited)	figures December 31, 2021 (Unaudited)	ended Mar 31, 2022 (Audited)	December 31, 2022 (Unaudited)	September 30, 2022 (Unaudited)	figures December 31, 2022 (Unaudited)	quarter of previous year ended December 31, 2021 (Unaudited)	figures December 31, 2021 (Unaudited)	ended Mar 31, 2022 (Audited)								
1	Total Income from Operations	16,869.13	17,108.92	47,369.94	16,166.11	38,399.63	56,597.73	16,869.13	17,108.92	47,369.94	16,374.24	38,868.11	56,856.03								
2	Net Profit/(Loss) for the period (before tax and exceptional items)	672.84	(332.29)	(1,068.38)	(899.29)	(302.61)	(5,277.04)	672.84	(332.29)	(1,068.38)	(1,386.32)	463.52	(5,689.87)								
3	Net Profit/(Loss) for the period before tax (after exceptional items)	672.84	(332.29)	(1,068.38)	(899.29)	(302.61)	(5,277.04)	672.84	(332.29)	(1,068.38)	(1,386.32)	463.52	(5,689.87)								
4	Net Profit/(Loss) for the period after tax (after exceptional items)	672.73	(332.29)	(1,068.49)	(899.29)	(302.61)	(480.72)	672.73	(332.29)	(1,068.49)	(1,386.32)	463.52	157.15								
5	Other comprehensive income (net of tax)	(36.59)	(36.60)	(109.79)	15.34	47.89	142.30	(36.59)	(36.60)	(109.79)	15.34	47.89	142.30								
6	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	636.14	(368.89)	(1,178.28)	(883.95)	(254.72)	(338.42)	721.99	(576.08)	(1,392.03)	(1,370.98)	511.41	(5,282.82)								
7	Equity Share Capital (face value of Rs.10 per share)	4,081.64	4,081.64	4,081.64	4,081.64	4,081.64	4,081.64	4,081.64	4,081.64	4,081.64	4,081.64	4,081.64	4,081.64								
8	Reserves (excluding Revaluation Reserve)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA								
9	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)																				
	a. Basic	1.65	(0.81)	(2.62)	(2.20)	(0.74)	(1.18)	1.86	(1.32)	(3.14)	(3.40)	1.14	(0.48)								
	b. Diluted	1.65	(0.81)	(2.62)	(2.20)	(0.74)	(1.18)	1.86	(1.32)	(3.14)	(3.40)	1.14	(0.48)								

Note:

- The above is an extract of the detailed format of the quarterly Consolidated and Standalone un-Audited financial results for the quarter ended December 31, 2022 filed with the stock exchanges under Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015. The full format of the un-Audited Consolidated and Standalone Financial Results for the quarter ended December 31, 2022 are available on the website of the BSE Limited i.e. [www.bseindia.com](http://www.bseindia.com) and National Stock Exchange of India Limited i.e. [www.nseindia.com](http://www.nseindia.com), on the stock exchanges where the Company's shares are listed and on the website of the Company i.e., [www.orchidpharma.com](http://www.orchidpharma.com)

For and on behalf of the Director of  
Orchid Pharma Limited

Place : Chennai

Date : February 09, 2023

Sd/-  
Manish Dhanuka  
Managing Director  
DIN : 00238798



### The Sandur Manganese & Iron Ores Limited

CIN:L85110KA1954PLC000759

#### STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2022

₹ in lakh

Sl. No.	Particulars	Standalone				Consolidated				
		Three months ended	Preceding three months ended	Corresponding three months ended in the previous year	Year to date figures for nine months ended	Corresponding nine months ended in the previous year	Previous year ended	Three months ended	Preceding three months ended	Year to date figures for nine months ended
		31.12.2022 (Unaudited)								

